Business
Collaboration with SGSC
Collaboration with SGSC.
About this update from Nuformix Plc
[{"type":"text","content":"\n \nRNS Number : 5743S Nuformix PLC 26 June 2018 \n\n \n \n \nNuformix Plc\n(\"Nuformix\" or \"the Company\")\n \nCollaboration with St George Street Capital\n \nNuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has entered into an initial collaboration with St George Street Capital ('SGSC').\n \nUnder the terms of the agreement SGSC and Nuformix will collaborate to generate new IP to support near-term SGSC clinical trials. If successful, SGSC and Nuformix will extend the collaboration across further SGSC clinical programmes where appropriate. \n \nDr Dan Gooding, CEO, Nuformix plc, said: \"St George Street Capital shares core objectives with Nuformix - those of rapidly unlocking the therapeutic potential of various known drugs to transform patient lives. The conclusion of this Agreement allows Nuformix to consider new options which have the potential to in build out its collaborative pipeline. \n \n\"Whilst focussing on making significant strides forward in its lead programmes, collaborative programmes allow Nuformix to create additional value with reduced risk. In this first collaborative announcement, we're delighted to support St George Street Capital from its inception as we both seek to address previously underserved patient populations with innovative treatments.\"\n \nMike Johnson, Managing Director of SGS said: \"I am delighted to announce the progress we have made in such a short time - we will work collaboratively with those organisations that apply bold new thinking and lateral approaches to help get treatments as quickly as possible to the people who need them. Nuformix is one of those companies that we believe will be instrumental in helping us accelerate treatments to patients\"\n \nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.\n \nEnquiries:\n\n\n\n\nNuformix Plc\nDan Gooding, CEO\n \n\n\n+44 (0) 1223 423667\n\n\n\n\nGable Communications Limited\nJohn Bick / Justine James\n\n\n+44 (0) 20 7193 7463\n \n\n\n\n\n \n \nAbout Nuformix plc\nNuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small mo...